INTRODUCTION
ATCs, Thyroid cancer, aggressive disease, thyroid cancer
THYROID CANCER, ANAPLASTIC THYROID CANCER, THYROID CANCER
Anaplastic thyroid cancer (ATC) is an extremely aggressive disease. It originates from follicular thyroid cells. It is the most dedifferentiated subtype of thyroid cancer and does not retain any biological characteristics of the follicular cells. Thyroid cancer stem cells can also play a role in the initiation and growth of ATCs. BRAF V600E mutation occurs in 25%–45% of the ATCs.Anaplastic thyroid cancer has an overall survival of 6 months following diagnosisHowever, effective therapeutic options for patients with wild‐type BRAF are lacking. Immunotherapy with anti‐PD‐L1 antibodies, alone or in combination with BRAF inhibitors, has shown promising result for the treatment of ATC.We report a case of a patient with locally advanced, unresectable ATC who was treated with famitinib and camrelizumab, allowing us to perform complete surgical resection, followed by postoperative radiation therapy.